TerminatedPhase 2

Open-Label Study of Intravitreal ICON-1 in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration (AMD)

Stopped: Business Reasons

United States15 participantsStarted 2018-03-26

Plain-language summary

The purpose of this study is to evaluate the safety and effects of repeated intravitreal injections of ICON-1 0.6 mg administered as maintenance therapy or in combination with aflibercept in patients with wet macular degeneration.

Who can participate

Age range50 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Males or females of any race, ≥50 years of age * Active primary CNV secondary to AMD in the study eye Exclusion Criteria: * Any prior treatment of CNV or advanced AMD in the study eye, except for dietary supplements or vitamins * Any intraocular or ocular surface surgery (including cataract surgery and laser procedures) in the study eye within 3 months * Vitrectomy in the study eye

What they're measuring

Change in Choroidal Neovascularization (CNV) Over Time

Timeframe: Month 9

Trial details

NCT IDNCT03452527

SponsorIconic Therapeutics, Inc.

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2019-04-25

Results submitted2020-09-01

View on ClinicalTrials.gov More Choroidal Neovascularization trials